Boston Scientific is making a big bet on a heart valve that hasn't even hit the market yet. The company said Monday it invested $1.5 billion in privately held MiRus, picking up roughly a 34% equity stake and an exclusive option to buy MiRus's transcatheter aortic valve replacement (TAVR) business. The deal is all about the SIEGEL Balloon Expandable TAVR system, an investigational device designed to treat severe aortic stenosis.

The SIEGEL valve is still experimental — it hasn't been approved for sale anywhere — but Boston Scientific sees enough promise to put serious money on the table. Under the agreement, the company could pay up to an additional $3 billion if MiRus hits certain clinical and regulatory milestones. That's a potential total outlay of $4.5 billion for a product that's still in trials.

So what makes this valve special? MiRus says the SIEGEL is built with a proprietary nitric oxide-coated rhenium alloy frame and dry porcine tissue leaflets. The company claims the frame offers greater radial strength than cobalt or titanium while eliminating foreshortening, which should allow for more precise placement during the procedure. And the delivery system is notably smaller: all three valve sizes — 23 mm, 26 mm, and 29 mm — can be delivered through an 8 French expandable sheath, which MiRus says is about 50% smaller than current commercial TAVR delivery sheaths. That could make the procedure less invasive and easier for doctors to perform.

Boston Scientific is clearly looking to strengthen its cardiovascular portfolio, and the TAVR market is a big opportunity. Aortic stenosis is a common and serious condition, especially in older adults, and less invasive valve replacement procedures have become increasingly popular. But the market is competitive, with players like Edwards Lifesciences and Medtronic already well established. Boston Scientific is betting that the SIEGEL valve's design — particularly its nickel-free frame and smaller sheath — can help it carve out a niche.

MiRus recently launched the STAR pivotal trial, which will evaluate the SIEGEL valve in up to 1,025 patients with severe symptomatic aortic stenosis across low-, intermediate-, and high-risk surgical groups. The results will be critical for regulatory approval and for convincing doctors to adopt the new system.

Investors seemed to like the news. Boston Scientific shares were up 5.56% at $55.61 on Monday. But the stock has had a rough year: it's down about 42% year-to-date, compared to a 7.4% gain for the S&P 500. Over the past month, BSX has fallen about 8.82% while the S&P 500 rose 3.9%. The MiRus deal might give the stock a short-term boost, but the real payoff — if it comes — will depend on how the SIEGEL valve performs in the clinic and whether it can win over regulators and cardiologists.